Copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2001
As a medical editor who works in the area of blood lipids and coronary heart disease risk, I was called on to review literature on rhabdomyolysis related to the use of cerivastatin. As you know, cerivastatin was voluntarily withdrawn from the market by Bayer Pharmaceutical Division, West Haven, Conn, in August 2001 because of reports of sometimes fatal rhabdomyolysis.1 In a case report published in the ARCHIVES in March of this year, Garcia-Valdecasas-Campelo et al2 write that "no [previous] cases of rhabdomyolysis associated with cerivastatin therapy have been described." Yet even my quick PubMed search showed at least 5 reports published in 1999 or 2000 of rhabdomyolysis in cerivastatin users.3-7 In 4 of 5 cases, cerivastatin was given in conjunction with gemfibrozil3,4,6,7; in the fifth, concomitant therapy included immunosuppressant drugs for renal transplantation.5 It strikes me that there was a serious breakdown in the peer review process of the ARCHIVES, especially given that claims of primacy should always be viewed with some skepticism. Had your peer reviewers been more careful, perhaps clinicians would have been more aware of a problem that would lead to a drug's withdrawal.
Simpson S. Case Reports of Rhabdomyolysis Associated With Cerivastatin Therapy. Arch Intern Med. 2001;161(21):2630–2631. doi:
Customize your JAMA Network experience by selecting one or more topics from the list below.